Clinical insights from a leader in kidney cancer research on the differences between clear cell and non–clear cell renal cell carcinoma.
Videos
Jamie L. Koprivnikar, MD, reviews luspatercept as a treatment option in myelodysplastic syndrome and the adverse events most frequently seen with her patients in clinical practice.
Following their review of data from the IASLC 2023 World Conference on Lung Cancer with expert Stephen Liu, MD, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, highlight key takeaways and future directions in care.
Shared insight into data from the EVOKE-02 study of sacituzumab govitecan in combination with pembrolizumab in patients with non–small cell lung cancer stratified by PD-L1 expression.
Switching their focus to the mesothelioma treatment space, Stephen Liu, MD, and Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, consider the role of surgical resection following data from MARS2.
Key opinion leaders review data from the CHRYSALIS-2 trial and consider the optimal utilization of amivantamab and lazertinib in combination in the setting of non–small cell lung cancer management.
Expert Stephen Liu, MD, joins the Oncology Brothers to share insight into updated data from the FLAURA2 trial of osimertinib with or without chemotherapy in patients with metastatic non–small cell lung cancer.
Yi Lin MD, PhD, discusses the impact of the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of relapsed or refractory multiple myeloma.
Dr Matthew A. Powell shares some closing thoughts on emerging agents and combination therapies in the endometrial cancer treatment landscape.
Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.
Matthew A. Powell, MD, reviews key takeaways from the Study-309/KEYNOTE-775 trial investigating lenvatinib plus pembrolizumab for the treatment for endometrial cancer.
Expert perspective on the impact of neuropathy on treatment choices in urothelial cancer, providing insight into identifying and managing peripheral neuropathy and exploring suitable treatment options.
Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.
Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.
Dr Matthew A. Powell details the rationale for using single-agent immunotherapy treatments for patients with advanced or recurrent endometrial cancer with reference to data updates from several key clinical trials.
Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.
The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.
Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.
Matthew A. Powell, MD, shares an overview of the systemic treatment options for patients with relapsed or metastatic endometrial cancer and the factors he considers when selecting an appropriate frontline therapy.
Arlene Siefker-Radtke, MD, discusses the nuanced treatment journey of a 73-year-old man with metastatic bladder cancer, highlighting the challenges and evolving strategies in his case.
Dr Matthew A. Powell reviews the study design and key endpoints of the RUBY trial in dMMR endometrial cancer and explains the potential clinical implications of the data.
Medical expert provides an overview of the recommended biomarker testing for endometrial cancer and the frontline treatment options available for patients with dMMR/MSI-high endometrial cancer.
Warren C. Swegal, MD, discusses the role of cabozantinib (Cabometyx) for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC).
Aaron T. Gerds, MD, MS, provides advice to community oncologists on how to utilize momelotinib for patients with myelofibrosis.
Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Adding immunotherapy to chemotherapy is the new standard-of-care treatment for advanced or recurrent endometrial cancer, according to Eirwen Miller, MD.
Skye Montoya, discusses research that she was a part of on mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.
Hatem Soliman, MD, discusses second- and third-line strategies being used for the treatment of patients with HER2-positive metastatic breast cancer.
Aaron T. Gerds, MD, MS, highlights exciting treatment options on the horizon for patients with myelofibrosis.